Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases this summer.
The Details:
According to a report from NBC News, experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of COVID-19 infections in the U.S. and experts believe its mutations have made the variant more immune evasive.
Much remains unknown about the KP.2 variant, however, research from Japan suggests current COVID-19 vaccines may be less effective against KP.2 than against previous variants.
The same research also suggests KP.2 might be less efficient at infecting cells, making the new variant more difficult to transmit and less likely to cause severe symptoms. Experts are predicting a rise in COVID-19 cases, however, they expect the rise to be smaller than in previous years.
Shares of vaccine-makers, including BioNTech SE (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are climbing as COVID-19 headlines return to the spotlight.
Moderna, Inc. (NASDAQ:MRNA) shares are trading at new 52-week highs following the report, and Pfizer, Inc. (NYSE:PFE) shares are also moving higher.
BNTX, NVAX, MRNA, PFE Price Action: According to Benzinga Pro, BioNTech shares are up 8.58% at $99.97, Novavax shares are up 7.38% at $16.01, Moderna shares are up 10.2% at $158.29 and Pfizer shares are up 2.45% at $29.26 at the time of publication Wednesday.
疫苗生产商的股票周三上涨,原因是有报道称,疾病专家预测今年夏天 COVID-19 病例将小幅上升。
细节:
根据美国全国广播公司新闻的报道,专家预测,随着一种新的占主导地位的菌株传播,COVID-19 病例将小幅增加。新菌株KP.2占美国 COVID-19 感染的28%,专家认为其突变使该变种更具免疫逃避能力。
关于KP.2变体还有很多未知数,但是,日本的研究表明,目前的 COVID-19 疫苗对KP.2的有效性可能不如对以前的变体。
同一项研究还表明,KP.2感染细胞的效率可能较低,这使得新变种更难传播,也不太可能引起严重症状。专家预测,COVID-19 病例将增加,但是,他们预计增幅将小于往年。
随着 COVID-19 的头条新闻重新成为人们关注的焦点,包括BioNTech SE(纳斯达克股票代码:BNTX)和Novavax, Inc.(纳斯达克股票代码:NVAX)在内的疫苗生产商的股价正在攀升。
报告发布后,摩德纳公司(纳斯达克股票代码:MRNA)股价创下52周新高,辉瑞公司(纽约证券交易所代码:PFE)的股价也在走高。
BNTX、NVAX、MRNA、PFE价格走势:根据Benzinga Pro的数据,BioNTech股价上涨8.58%,至99.97美元,Novavax股价上涨7.38%,至16.01美元,Moderna股价上涨10.2%,至158.29美元,辉瑞股价上涨2.45%,至29.26美元。